Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Special issues
    • Subject collections
    • Cell Scientists to Watch
    • First Person
    • Sign up for alerts
  • About us
    • About JCS
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Fast-track manuscripts
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • JCS Prize
    • Manuscript transfer network
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contacts
    • Contact JCS
    • Subscriptions
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Journal of Cell Science
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Journal of Cell Science

  • Log in
Advanced search

RSS   Twitter  Facebook   YouTube  

  • Home
  • Articles
    • Accepted manuscripts
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Special issues
    • Subject collections
    • Cell Scientists to Watch
    • First Person
    • Sign up for alerts
  • About us
    • About JCS
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Fast-track manuscripts
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • JCS Prize
    • Manuscript transfer network
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contacts
    • Contact JCS
    • Subscriptions
    • Advertising
    • Feedback
Research Article
Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function
Lingxiao Tan, Kwang-Jin Cho, Walaa E. Kattan, Christian M. Garrido, Yong Zhou, Pratik Neupane, Robert J. Capon, John F. Hancock
Journal of Cell Science 2019 132: jcs232132 doi: 10.1242/jcs.232132 Published 31 July 2019
Lingxiao Tan
1Department of Integrative Biology and Pharmacology, McGovern Medical School University of Texas Health Science Center at Houston, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lingxiao Tan
Kwang-Jin Cho
2Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kwang-Jin Cho
Walaa E. Kattan
1Department of Integrative Biology and Pharmacology, McGovern Medical School University of Texas Health Science Center at Houston, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian M. Garrido
2Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Zhou
1Department of Integrative Biology and Pharmacology, McGovern Medical School University of Texas Health Science Center at Houston, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pratik Neupane
3Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Capon
3Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland 4072, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John F. Hancock
1Department of Integrative Biology and Pharmacology, McGovern Medical School University of Texas Health Science Center at Houston, Houston, TX 77030, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John F. Hancock
  • For correspondence: john.f.hancock@uth.tmc.edu
  • Article
  • Figures & tables
  • Supp info
  • Info & metrics
  • PDF + SI
  • PDF
Loading

Article Figures & Tables

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    APEH is bound and inhibited by G01. (A) Structure of B-G01. (B) Beads collected from cell lysates incubated with or without B-G01 were analyzed by silver staining. The band that was analyzed by mass spectrometry is indicated (arrow). (C) Beads collected from 200 μg cell lysates incubated with or without B-G01 were immunoblotted for APEH. Controls including 20 μg whole-cell lysate (input) were immunoblotted for APEH and β-actin. Representative blots were shown. (D) Lysates of MDCK cells transfected with NT shRNA or APEH shRNAs were blotted for APEH. The level of APEH was normalized to the level of β-actin. Representative western blots are shown. **P<0.01 between APEH knockdown and control APEH levels (one-way ANOVA). Lysates were incubated with 1 mM ac-Ala-pNA for 2 h at 37°C. Absorbance at 410 nm was measured at intervals. ***P<0.001 (one-way ANOVA). Results are mean±s.e.m. (n=3). (E) MDCK cell lysates were incubated with vehicle (DMSO) or 50 μM G01 for 1 h at room temperature and 1 mM ac-Ala-pNA was added. Absorbance at 410 nm was measured following warming to 37°C. Results are mean±s.e.m. (n=3). ***P<0.001 between DMSO- and G01-treated background-subtracted absorbance (Student's t-tests). (F) Box plots indicating quartiles of APEH expression level in patient tissues (n=20,163) of 33 types of cancers with or without KRAS mutants were generated using the UCSC Xena Browser. Whiskers represent upper and lower quartiles. The statistical significance was analyzed with Welch's t-test.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    APEH inhibition or knockdown inhibits KRASG12V PM localization and nanoclustering. (A) Structure of G01 and ebelactone. (B) MDCK cells stably expressing mGFP–KRASG12V and mCherry–CAAX transfected with NT shRNA or APEH shRNAs were lysed and blotted for APEH. The level of APEH was normalized to the level of β-actin. Representative western blots are shown. Results are mean±s.e.m. (n=3). **P<0.01 between APEH-knockdown and control APEH levels (one-way ANOVA). (C) Cells treated as in B together with MDCK cells stably expressing mGFP–KRASG12V and mCherry–CAAX and treated with ebelactone or G01 for 48 h were imaged in a confocal microscope. Representative images are shown. Scale bar: 10 μm. (D) Upper left, the extent of KRAS mislocalization was quantified by determining the Manders’ coefficients, which evaluate the extent of colocalization of mCherry–CAAX and mGFP–KRASG12V. Results are mean±s.e.m. (n=3). ***P<0.001 between APEH-knockdown and control Manders’ coefficients (one-way ANOVA). Upper right and bottom left, estimated IC50 values for ebelactone or G01 were obtained from the respective Manders’ coefficient (mean±s.e.m.; n=3) dose–response plots. (E) MDCK cells stably expressing mGFP–KRASG12V transfected with NT shRNA or APEH shRNAs were lysed and blotted for APEH. The level of APEH was normalized to the level of β-actin. Representative western blots are shown. Results are mean±s.e.m. (n=3). ***P<0.001 between APEH-knockdown and control APEH levels (one-way ANOVA). (F) Basal PM sheets were generated from cells from E and imaged by EM after incubation with anti-GFP antibody conjugated to 4.5 nm gold particles. Left, the extent of clustering was analyzed with Ripley's K-function expressed as L(r)−r functions, and normalized on the 99% confidence interval (c.i.). Lmax, which is the maximum value of L(r)−r, serves as the summary statistic. Values of Lmax above the c.i. indicate clustering, with the extent of clustering given by the value of Lmax (mean±s.e.m.; n≥12). *P<0.05; **P<0.01 comparing the pattern for control cells with that for APEH knockdown cells (bootstrap tests). Right, gold labeling density on the PM sheets is shown as mean±s.e.m. (n≥12). *P<0.05; **P<0.01 for the difference in gold labeling density (one-way ANOVA). (G) Lmax and gold labeling density calculated as in F of basal PM sheets generated from cells treated with vehicle (DMSO) or ebelactone or G01 for 48 h.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Expression of exogenous APEH rescues the KRASG12V mislocalization induced by APEH knockdown or G01 treatment. (A) Cells as in Fig. 2B were transfected with 0.25 μg APEH–Myc cDNA and imaged in a confocal microscope. Representative images are shown. (B) Parallel cultures of the cells as in A were analyzed by immunoblotting. Representative blots are shown. (C) The extent of KRAS mislocalization was quantified by determining the Manders’ coefficients. ***P<0.001 (Student's t-test). (D) MDCK cells stably expressing mGFP–KRASG12V and mCherry–CAAX were transfected with 0.5 or 2.5 μg APEH–Myc cDNA and lysed for immunoblotting. Representative blots are shown. (E) Parallel cultures of the cells as in D were imaged in a confocal microscope and representative images are shown. The extent of KRAS mislocalization was quantified by determining the Manders’ coefficients. There was no significant difference between APEH-overexpressing and control cells (one-way ANOVA). (F) Cells as in D were seeded on 12-well plates and treated with vehicle (DMSO) or G01 for 48 h. Representative images are shown. The extent of KRAS mislocalization was quantified by determining the Manders’ coefficients. **P<0.01; ***P<0.001 compared with cells without APEH overexpression (one-way ANOVA). (G) MDCK cells stably expressing mGFP–KRASG12V and mCherry–CAAX were treated with vehicle (DMSO) or bortezomib for 48 h. Cells were imaged in a confocal microscope. Representative images are shown. The extent of KRAS mislocalization was quantified determining the Manders’ coefficients. Estimated IC50 values were obtained from the respective Manders’ coefficients dose–response plots. All graphs show mean±s.e.m. (n=3). Scale bars: 10 μm.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    PtdSer and cholesterol are mislocalized upon APEH knockdown or inhibition. (A) MDCK cells stably expressing mGFP–LactC2 and mCherry–D4H were transfected with NT shRNA or APEH shRNAs and lysed for quantitative immunoblotting. The level of APEH was normalized to the level of β-actin. Representative western blots are shown. Results are mean±s.e.m. (n=3). ***P<0.001 between APEH-knockdown and control cells (one-way ANOVA). (B) Parallel cultures of cells as in A were imaged in a confocal microscope. Representative images are shown. (C) MDCK cells stably expressing mGFP–LactC2 and mCherry–D4H were treated with vehicle (DMSO) or staurosporine (STS) or ebelactone or G01 for 48 h and imaged in a confocal microscope. Representative images are shown. (D) Left, MDCK cells stably expressing mGFP–LactC2 and mCherry–CAAX were transfected with NT shRNA or APEH shRNAs and imaged in a confocal microscope. The extent of LactC2 mislocalization was quantified by determining the Manders’ coefficients. ***P<0.001 (one-way ANOVA). Middle and right, MDCK cells stably expressing mGFP–LactC2 and mCherry–CAAX were treated with G01 or ebelactone for 48 h and imaged in a confocal microscope. The extent of LactC2 mislocalization was quantified by determining the Manders’ coefficients. Estimated IC50 values for ebelactone or G01 were obtained from the respective Manders’ coefficient dose–response plots. Results are mean±s.e.m. (n=3). Scale bars: 10 μm.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    The endocytic recycling of EGFR is disrupted by APEH knockdown or inhibition. (A) CHO cells stably expressing mGFP–EGFR were transfected with NT shRNA or APEH shRNAs and lysed for quantitative immunoblotting. The level of APEH was normalized to the level of β-actin. Results are mean±s.e.m. (n=3). Representative western blots are shown. ***P<0.001 between APEH-knockdown and control APEH levels (one-way ANOVA). (B) Cells as in A were serum-starved for 2 h and incubated with 50 ng/ml EGF on ice for 20 min. Excess EGF was washed away and cells were incubated with fresh warm medium. Cells were fixed at different time points and imaged in a confocal microscope. Representative images are shown. (C) CHO cells stably expressing mGFP–EGFR were treated with vehicle (DMSO) or ebelactone. Cells were serum-starved for 2 h and incubated with 50 ng/ml EGF on ice for 20 min. Excess EGF was washed away and cells were incubated with fresh warm medium. Cells were fixed at different time points and imaged in a confocal microscope. Representative images are shown. Scale bars: 10 μm.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    APEH knockdown does not alter cellular SM levels. (A) Cells as in Fig. 1D were stained with GFP–lysenin and imaged in a confocal microscope with fixed imaging parameters to compare fluorescence intensities. Representative images are shown. The GFP fluorescence intensity was quantified using ImageJ and normalized to the mean of those in NT shRNA group (set at one). Results are mean±s.e.m. (n≥12). There was no significant difference in the relative fluorescence intensity (one-way ANOVA). (B) Cells as in Fig. 1D were stained with GFP–lysenin and DAPI following by cell permeabilization. Cells were imaged in a confocal microscope with fixed imaging parameters for comparison of fluorescent intensities. Representative images are shown. (C) MDCK cells were treated with vehicle (DMSO), staurosporine (STS), ebelactone or G01 for 48 h, and imaged and analyzed as in A. *P<0.05; **P<0.01; ***P<0.001 compared with DMSO (one-way ANOVA). (D) MDCK cells were treated with vehicle (DMSO), STS, ebelactone or G01 for 48 h and permeabilized. Cells were stained with GFP–lysenin and DAPI and were imaged as in B. Representative images are shown. (E) MDCK cells were treated with vehicle (DMSO), GW4869, G01 or ebelactone for 48 h and lysed. Cell lysates were analyzed for neutral and acid SMase activity. ***P<0.001 (one-way ANOVA). (F) Cells as in Fig. 1D were lysed and analyzed for neutral and acid SMase activity. There was no significant difference between the control and knockdown cells (one-way ANOVA). Graphs in E and F show mean±s.e.m. (n=3). Scale bars: 10 μm.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    MAPK signaling is reduced by APEH knockdown or inhibition. (A) MDCK cells expressing KRASG12V were treated with vehicle (DMSO) or ebelactone or G01 for 48 h. These cells, together with the cells as in Fig. 2E, were lysed for quantitative immunoblotting. Representative blots are shown. (B) Levels of ppERK were normalized to the total level of ERK. Levels of KRASG12V, APEH, and endogenous RAS were normalized to the total level of β-actin. Results are mean±s.e.m. (n=3). *P<0.05; **P<0.01; ***P<0.001 between drug-treated or shRNA-transfected and control protein levels (one-way ANOVA).

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    The proliferation of KRAS-dependent pancreatic cancer cells is inhibited by APEH knockdown or inhibition. BxPC-3, MiaPaCa-2, MOH, PANC-1 and MPanc-96 cells were transfected with NT shRNA or APEH shRNAs and lysed for quantitative immunoblotting. The level of APEH was normalized to the level of β-actin. *P<0.05; **P<0.01; ***P<0.001 between APEH-knockdown and control APEH cells (one-way ANOVA). (B) Cells as in A were grown in 12-well plates for 6 days. Cells were counted every 48 h. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA). (C) BxPC-3, MiaPaCa-2, MOH, PANC-1 and MPanc-96 cells were treated with vehicle (DMSO) or daily doses of two concentrations of G01 in 12-well plates for 6 days. Cells were counted every 48 h. *P<0.05; **P<0.01; ***P<0.001 (one-way ANOVA). All graphs show mean±s.e.m. (n=3).

Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

Keywords

  • KRAS
  • Acylpeptide hydrolase
  • Recycling endosome
  • Oxanthroquinone
  • Plasma membrane
  • Sphingomyelin metabolism

 Download PDF

Email

Thank you for your interest in spreading the word on Journal of Cell Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function
(Your Name) has sent you a message from Journal of Cell Science
(Your Name) thought you would like to see the Journal of Cell Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Research Article
Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function
Lingxiao Tan, Kwang-Jin Cho, Walaa E. Kattan, Christian M. Garrido, Yong Zhou, Pratik Neupane, Robert J. Capon, John F. Hancock
Journal of Cell Science 2019 132: jcs232132 doi: 10.1242/jcs.232132 Published 31 July 2019
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Research Article
Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function
Lingxiao Tan, Kwang-Jin Cho, Walaa E. Kattan, Christian M. Garrido, Yong Zhou, Pratik Neupane, Robert J. Capon, John F. Hancock
Journal of Cell Science 2019 132: jcs232132 doi: 10.1242/jcs.232132 Published 31 July 2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • Footnotes
    • References
  • Figures & tables
  • Supp info
  • Info & metrics
  • PDF + SI
  • PDF

Related articles

Cited by...

More in this TOC section

  • Histone chaperone APLF level dictates the implantation of mouse embryos
  • Switching between blebbing and lamellipodia depends on the degree of non-muscle myosin II activity
  • Kindlin-2 promotes rear focal adhesion disassembly and directional persistence during cell migration
Show more RESEARCH ARTICLE

Similar articles

Other journals from The Company of Biologists

Development

Journal of Experimental Biology

Disease Models & Mechanisms

Biology Open

Advertisement

2020 at The Company of Biologists

Despite the challenges of 2020, we were able to bring a number of long-term projects and new ventures to fruition. While we look forward to a new year, join us as we reflect on the triumphs of the last 12 months.


Mole – The Corona Files

"This is not going to go away, 'like a miracle.' We have to do magic. And I know we can."

Mole continues to offer his wise words to researchers on how to manage during the COVID-19 pandemic.


Cell scientist to watch – Christine Faulkner

In an interview, Christine Faulkner talks about where her interest in plant science began, how she found the transition between Australia and the UK, and shares her thoughts on virtual conferences.


Read & Publish participation extends worldwide

“The clear advantages are rapid and efficient exposure and easy access to my article around the world. I believe it is great to have this publishing option in fast-growing fields in biomedical research.”

Dr Jaceques Behmoaras (Imperial College London) shares his experience of publishing Open Access as part of our growing Read & Publish initiative. We now have over 60 institutions in 12 countries taking part – find out more and view our full list of participating institutions.


JCS and COVID-19

For more information on measures Journal of Cell Science is taking to support the community during the COVID-19 pandemic, please see here.

If you have any questions or concerns, please do not hestiate to contact the Editorial Office.

Articles

  • Accepted manuscripts
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Special issues
  • Subject collections
  • Interviews
  • Sign up for alerts

About us

  • About Journal of Cell Science
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Journal Meetings
  • Workshops
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Fast-track manuscripts
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • JCS Prize
  • Manuscript transfer network
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Sign up for alerts

Contacts

  • Contact JCS
  • Subscriptions
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2021   The Company of Biologists Ltd   Registered Charity 277992